Brokerages Set Metsera Inc. (NASDAQ:MTSR) Target Price at $55.75

by · The Cerbat Gem

Shares of Metsera Inc. (NASDAQ:MTSR – Get Free Report) have been given a consensus rating of “Hold” by the eight research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $55.75.

MTSR has been the subject of several research analyst reports. Leerink Partners restated a “market perform” rating and set a $57.00 price target (down from $77.00) on shares of Metsera in a research report on Wednesday, September 24th. Wall Street Zen raised Metsera from a “sell” rating to a “hold” rating in a research note on Wednesday, October 1st. Bank of America raised their target price on Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Leerink Partnrs lowered shares of Metsera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 24th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Metsera in a research report on Wednesday, October 8th.

Get Our Latest Stock Report on MTSR

Hedge Funds Weigh In On Metsera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Metsera by 290.6% in the third quarter. Vanguard Group Inc. now owns 5,824,993 shares of the company’s stock worth $304,822,000 after acquiring an additional 4,333,514 shares in the last quarter. Wellington Management Group LLP increased its holdings in Metsera by 6.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,659,465 shares of the company’s stock worth $191,500,000 after purchasing an additional 232,033 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in Metsera in the 1st quarter valued at about $78,748,000. Alpha Wave Global LP purchased a new position in shares of Metsera in the 1st quarter valued at about $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Metsera in the 1st quarter valued at about $42,395,000.

Metsera Price Performance

Shares of MTSR opened at $70.50 on Monday. The firm has a 50-day simple moving average of $63.43 and a two-hundred day simple moving average of $44.76. The stock has a market cap of $7.42 billion and a PE ratio of -11.16. Metsera has a 1-year low of $12.30 and a 1-year high of $83.86.

Metsera (NASDAQ:MTSR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.55).

Metsera Company Profile

(Get Free Report)

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Featured Stories